BeNeLuxBelgiumNetherlandsLuxembourg

Qiagen to acquire stake in Alacris

12.01.2011

Hilden/Berlin – Qiagen NV has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a pioneer in the field of deep sequencing based therapy guidance, clinical trial stratification, and biomarker identification. With its minority stake, Qiagen acquires an exclusive option to access all biomarkers dicovered with Alacris’ ModCell™ system. Alacris will participate in commercialization of these biomarkers through royalty fees. Financial details of the agreement were not disclosed. ModCell™, which was invented by Alacris co-founder Prof. Hans Lehrach from Max Planck Institute for Molecular Genetics (MPI-MG) in Berlin uses a proprietary modelling system and can be used to identify the right therapy for a specific genotype (patient) and also to identify the right genotypes for a therapy (clinical trial stratification). The latter of the two applications leads to the identification of a companion diagnostic or biomarker set for that therapy. These marker selections can be formatted into real-time PCR-based assays that QIAGEN can then commercialize within its pharmaceutical development assay portfolio or its therascreen molecular diagnostics portfolio for use on its new QIAsymphony RGQ platform. “Our strategic investment in Alacris expands QIAGEN’s existing broad biomarker discovery and validation initiatives and is designed to expand our QIAsymphony-based personalized healthcare and pharma development assay portfolio,” said Peer Schatz, Chief Executive Officer of QIAGEN. “With QIAGEN, we have not only engaged a financially strong investor but also a leader in personalized healthcare as our partner,” said Prof. Dr. Hans Lehrach. Biomarkers play an increasingly important role in diagnostics and the development of new pharmaceutical agents. Experts estimate the overall market volume for biomarkers will be approximately $21 billion by 2012. The agreement will not affect marketing of Alacris’ sequencing-based therapy guidance to leading cancer clinics or clinical trial stratification business that is available to pharmaceutical companies in order to help them reduce the cost of bringing their oncology drugs to market and to increase the likelihood of a successful approval.

BeNeLuxBelgiumNetherlandsLuxembourg

29.03.2012

Brussels – Promethera Biosciences has completed a Series B financing round, generating proceeds of €23.6m. The Belgian cell therapy company secured a capital increase of €17m from its new investors, among them the venture arms...

BeNeLuxBelgiumNetherlandsLuxembourg

19.03.2012

Leuven – Biopharmaceutical company ThromboGenics has entered into an agreement with Alcon Inc., a division of Novartis for the commercialisation of its product ocriplasmin in all markets outside the U.S. ThromboGenics said it...

BeNeLuxBelgiumNetherlandsLuxembourg

07.03.2012

Amsterdam Molecular Therapeutics has announced a financial manoeuvre aimed at getting the biotech out of a hopeless situation. The assets and – more importantly – the liabilities of the drug developer will be acquired by a newly...

BeNeLuxBelgiumNetherlandsLuxembourg

20.02.2012

Amsterdam - Amsterdam Molecular Therapeutics has announced a financial manoeuvre which is aimed to get the biotech out of a dead end. The assets and – more importantly – the liabilities of the drug developer will be acquired by...

BeNeLuxBelgiumNetherlandsLuxembourg

10.02.2012

Glasgow/Leuven - With a little help from the EU, two biotech companies are banding together to develop the first stem cell therapy against rheumatoid arthritis. UK-based Sistemic will work with TiGenix to develop the Belgian's...

BeNeLuxBelgiumNetherlandsLuxembourg

25.01.2012

Amsterdam – Two elephants in the biofuels business join forces. Dutch food and chemicals group Royal DSM and POET, LLC, a US-based ethanol producer, announced a plan to build a commercial cellulosic ethanol plant. POET–DSM...

BeNeLuxBelgiumNetherlandsLuxembourg

13.01.2012

Heerlen - Royal DSM N.V will be the industrial partner to the Panoptes consortium, which aims to develop novel drug delivery technology for the posterior eye segment. The four year project is supported by EUR4m in funding from...

BeNeLuxBelgiumNetherlandsLuxembourg

04.01.2012

Leiden - Dutch Pharming Group NV has taken a further step to secure sound financing even beyond the recent milestone payments. The drug developer announced that it has entered into a financing of approximately €8.4 million by...

BeNeLuxBelgiumNetherlandsLuxembourg

16.12.2011

Ghent – Just days after US pharmaceuticals giant Pfizer pulled out of a rheumatoid arthritis pact with Ablynx NV, the Belgian biopharmaceutical company expanded its relationship with Merck Serono. Ablynx has now entered into a...

Displaying results 1 to 10 out of 304

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-benelux/article/qiagen-to-acquire-stake-in-alacris.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4290.4%
  • CO.DON2.51 EUR191.9%
  • PAION2.43 EUR164.1%

FLOP

  • CYTOS0.25 CHF-93.9%
  • MEDIGENE4.53 EUR-69.2%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 01.09.2014


Current issue

All issues

Product of the week

Products